Apremilast: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HIRA (South Korea), NICE (England) and TLV (Sweden) recommended or restricted apremilast, while AWMSG (Wales), CIPM (Spain) and NYE METODER (Norway) did not recommend it.
Assessment has run over 10.3 years, from 6 Jan 2015 at AWMSG (Wales) to 15 May 2025 at G-BA (Germany).
NICE (England) changed its position: recommended on 23 Nov 2016, restricted by 22 Feb 2017.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for apremilast, 1 submission was never made — an outcome set by the company rather than the assessor.
The file is active: 5 of 28 records date from 2023 or later.
The programme is broad: 12 distinct indication wordings are recorded for apremilast by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
12 of these 28 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess apremilast, on 6 Jan 2015; HIRA (South Korea) did not open a file until 10 Oct 2024 — an unusually long tail of 9.8 years between the earliest and latest system to look at it.
The record arrives in waves: 8 separate years each carry two or more decisions, spread across 10 years in total.
5 of the 10 agencies here assessed apremilast more than once, PBAC (Australia) most often at 12 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for apremilast.
The full ledger for apremilast reads 7 recommended, 6 other, 5 not recommended and 3 no benefit, with 7 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 15 May 2025 | Otezla — benefit assessment §35a | added benefit: not proven | source |
| HAS (France) | 26 Feb 2025 | Indication extension | SMR moderate · ASMR V | source |
| HIRA (South Korea) | 10 Oct 2024 | 건선성 관절염 건선 | reimbursable only at the evaluated price | source |
| PBAC (Australia) | 2023 | Psoriatic arthritis (PsA) | Not Recommended | source |
| CIPM (Spain) | 3 Feb 2022 | Indicaciones terapéuticas autorizadas: Artritis psoriásica Otezla, solo o en combinación con Fármacos Antirreumáticos Mo… | not financed by the SNS · art. 92 d, e | source |
23 further decisions for apremilast, across 8 agencies, are not shown here. They link to 10 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 28 decisions for apremilast from 10 agencies, 2015 to 2025. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.